Flow Cytometry (FC/FACS)
(Flow Cytometric analysis of TF-1 cells using MBS646918 (filled histogram) or PE-conjugated isotype control (open histogram).)
Mouse anti-Human Thrombopoietin Receptor Monoclonal Antibody | anti-MPL antibody
Thrombopoietin Receptor (TPO-R, Myeloproliferative Leukemia Protein, Proto-oncogene c-Mpl, CD110, TPOR) (PE)
Flow Cytometry:
1. TF-1 cells may be Fc-blocked with 1ug of human IgG/10e5 cells for 15 minutes at RT. Do not wash excess blocking IgG from this reaction.
2. After blocking, 10ul of MBS646918 was added to up to 1x10e6 cells and incubated for 30 minutes at RT.
3. Unbound antibody was removed by washing the cells twice in MBS635370: Flow Cytometry Staining Buffer. Note: whole blood requires a RBC lysis step at this point.
4. The cells were resuspended in Flow Cytometry Staining Buffer for final flow cytometric analysis. As a control for this analysis, cells in a separate tube should be treated with PE-labeled rmouse IgG2a antibody.
Optimal dilutions to be determined by the researcher.
Other applications not tested.
Flow Cytometry (FC/FACS)
(Flow Cytometric analysis of TF-1 cells using MBS646918 (filled histogram) or PE-conjugated isotype control (open histogram).)
Flow Cytometry (FC/FACS)
(Flow Cytometric analysis of TF-1 cells using MBS646918 (filled histogram) or PE-conjugated isotype control (open histogram).)
NCBI and Uniprot Product Information
NCBI Description
In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008]
Uniprot Description
Function: Receptor for thrombopoietin. May represent a regulatory molecule specific for TPO-R-dependent immune responses.
Subunit structure: Interacts with ATXN2L. Ref.8
Subcellular location: Membrane; Single-pass type I membrane protein.
Tissue specificity: Expressed at a low level in a large number of cells of hematopoietic origin. Isoform 1 and isoform 2 are always found to be coexpressed.
Domain: The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.The box 1 motif is required for JAK interaction and/or activation.
Post-translational modification: Ubiquitination at Lys-553 and Lys-573 targets MPL for degradation by both the lysosomal and proteasomal pathways. The E3 ubiquitin-protein ligase CBL significantly contributes to this ubiquitination.
Involvement in disease: Congenital amegakaryocytic thrombocytopenia (CAMT) [MIM:604498]: Disease characterized by isolated thrombocytopenia and megakaryocytopenia with no physical anomalies.Note: The disease is caused by mutations affecting the gene represented in this entry.Thrombocythemia 2 (THCYT2) [MIM:601977]: A myeloproliferative disorder characterized by excessive platelet production, resulting in increased numbers of circulating platelets. It can be associated with spontaneous hemorrhages and thrombotic episodes.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.9 Ref.13 Ref.14Myelofibrosis with myeloid metaplasia (MMM) [MIM:254450]: A chronic myeloproliferative disorder characterized by replacement of the bone marrow by fibrous tissue, extramedullary hematopoiesis, anemia, leukoerythroblastosis and hepatosplenomegaly.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.11 Ref.12
Sequence similarities: Belongs to the type I cytokine receptor family. Type 1 subfamily.Contains 2 fibronectin type-III domains.
Caution: It is uncertain whether Met-1 or Met-8 is the initiator.
Research Articles on MPL
Similar Products
Product Notes
The MPL mpl (Catalog #AAA646918) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Thrombopoietin Receptor (TPO-R, Myeloproliferative Leukemia Protein, Proto-oncogene c-Mpl, CD110, TPOR) (PE) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's Thrombopoietin Receptor can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS). FC/FACS: 10ul labels 1x10e6 cells using TF-1 human erythroleukemic cell line. Flow Cytometry: 1. TF-1 cells may be Fc-blocked with 1ug of human IgG/10e5 cells for 15 minutes at RT. Do not wash excess blocking IgG from this reaction. 2. After blocking, 10ul of MBS646918 was added to up to 1x10e6 cells and incubated for 30 minutes at RT. 3. Unbound antibody was removed by washing the cells twice in MBS635370: Flow Cytometry Staining Buffer. Note: whole blood requires a RBC lysis step at this point. 4. The cells were resuspended in Flow Cytometry Staining Buffer for final flow cytometric analysis. As a control for this analysis, cells in a separate tube should be treated with PE-labeled rmouse IgG2a antibody. Optimal dilutions to be determined by the researcher. Other applications not tested. Researchers should empirically determine the suitability of the MPL mpl for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "Thrombopoietin Receptor, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
